Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1

Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Here, we expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadivel, Kanagasabai, Zaiss, Anne K., Kumar, Yogesh, Fabian, Frank M., Ismail, Ayman E. A., Arbing, Mark A., Buchholz, Wallace G., Velander, William H., Bajaj, S. Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698382/
https://www.ncbi.nlm.nih.gov/pubmed/33212896
http://dx.doi.org/10.3390/jcm9113684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698382/
https://www.ncbi.nlm.nih.gov/pubmed/33212896
http://dx.doi.org/10.3390/jcm9113684

Ejemplares similares